TOVX

Theriva Biologics Inc

0.2499

Jun 30 • 02:31PM ET -0.0101 (-3.88%)

Healthcare Biotechnology USA Nano AMEX

Peers: BLRX CYCN ERNA GDTC GNTA GTBP ICU INTS MBRX RKTO

Scroll to Statements

Index	-
Market Cap	11.47M
Enterprise Value	0.73M
Income	-22.97M
Sales	0.30M
Book/sh	0.34
Cash/sh	0.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Dec 27, 2007
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Apr 05, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	38.22
P/B	0.74
P/C	0.79
P/FCF	-
EV/EBITDA	-
EV/Sales	2.42
Quick Ratio	1.63
Current Ratio	1.63
Debt/Eq	0.24
LT Debt/Eq	0.20
Option/Short	No / Yes

EPS (ttm)	-2.53
EPS next Y	-0.24
EPS next Q	-0.06
EPS this Y	89.18%
EPS next Y	-6.67%
EPS next 5Y	46.42%
EPS past 3/5Y	60.07% 58.31%
Sales past 3/5Y	- -
EPS Y/Y TTM	87.76%
Sales Y/Y TTM	-
EPS Q/Q	96.80%
Sales Q/Q	-
Earnings	May 05 AMC
EPS/Sales Surpr.	0.00% -

Insider Own	1.63%
Insider Trans	0.00%
Inst Own	4.28%
Inst Trans	1.25%
ROA	-60.96%
ROE	-138.91%
ROIC	-115.70%
Gross Margin	64.67%
Oper. Margin	-4452.67%
Profit Margin	-7656.33%
SMA20	-5.75%
SMA50	-18.73%
SMA200	-8.41%
Trades

Shs Outstand	45.89M
Shs Float	45.14M
Short Float	6.56%
Short Ratio	0.14
Short Interest	2.96M
52W High	0.86 -71.05%
52W Low	0.16 53.50%
Volatility	5.86% 11.17%
ATR (14)	0.03
RSI (14)	43.13
Beta	1.09
Rel Volume	0.02
Avg Volume	20.72M
Volume	396,998

Perf Week	-1.23%
Perf Month	-11.95%
Perf Quarter	34.94%
Perf Half Y	30.63%
Perf YTD	18.77%
Perf Year	-42.39%
Perf 3Y	-99.00%
Perf 5Y	-99.83%
Perf 10Y	-100.00%
Recom	1.00
Target Price	2.50
Prev Close	0.26
Price	0.25
Change	-3.88%

Jun-11-26 08:00AM	Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research (GlobeNewswire) +26.08%
May-05-26 04:43PM	Theriva Biologics: Q1 Earnings Snapshot (Associated Press)
04:30PM	Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results (GlobeNewswire)
Apr-17-26 04:05PM	Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting (GlobeNewswire) +59.41%
Mar-23-26 08:00AM	Theriva Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +8.42%
08:00AM	Loading…
Mar-12-26 08:00AM	Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results (GlobeNewswire)
Feb-18-26 08:00AM	Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications (GlobeNewswire) +6.25%
Feb-03-26 08:00AM	Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 (GlobeNewswire)
Dec-30-25 08:05AM	Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design (TipRanks)
Dec-29-25 08:00AM	Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (GlobeNewswire)
Nov-12-25 08:16AM	Theriva Biologics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%
08:00AM	Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results (GlobeNewswire)
Oct-24-25 02:31PM	Theriva Biologics Provides Response to Unusual Market Action (GlobeNewswire)
Oct-16-25 08:11AM	Theriva Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds (GlobeNewswire) -48.68%
Oct-13-25 08:00AM	Theriva Biologics Announces Upcoming Presentations at Medical Meetings (GlobeNewswire)
08:00AM	Loading…
Oct-06-25 08:00AM	Theriva Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (GlobeNewswire)
Aug-11-25 06:14PM	Theriva Biologics: Q2 Earnings Snapshot (Associated Press Finance) +14.02%
08:00AM	Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results (GlobeNewswire)
May-27-25 08:00AM	Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer (GlobeNewswire) -5.49%
May-14-25 08:40AM	Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results (GlobeNewswire)
08:22AM	Theriva Biologics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-25 04:30PM	Theriva Biologics Announces Closing of $7.5 Million Public Offering (GlobeNewswire) -20.59% -17.62%
May-07-25 09:30AM	Theriva Biologics announces pricing of $7.5M public offering (Seeking Alpha) -40.44%
09:17AM	Theriva Biologics Announces Pricing of $7.5 Million Public Offering (GlobeNewswire)
07:00AM	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients (GlobeNewswire)
Apr-10-25 08:00AM	Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire) +11.43%
Mar-31-25 08:00AM	Theriva Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (GlobeNewswire)
Mar-19-25 08:10AM	Theriva Biologics to Present at the 2025 NeauxCancer Conference (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-06-25 04:10PM	Theriva Biologics Reports Full-Year 2024 Operational Highlights and Financial Results (GlobeNewswire)
04:05PM	Loading…
Mar-05-25 04:05PM	Theriva Biologics to Participate in the Q1 Investor Summit Virtual (GlobeNewswire)
Dec-05-24 08:00AM	Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
Nov-12-24 08:23AM	Theriva Biologics: Q3 Earnings Snapshot (Associated Press Finance) -23.12%
08:00AM	Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Oct-31-24 04:05PM	Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant (GlobeNewswire) +36.30%
Oct-16-24 08:00AM	Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma (GlobeNewswire) +5.04%
Oct-03-24 10:45AM	Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients (Benzinga) +44.35%
08:00AM	Theriva Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Sep-26-24 09:06PM	Theriva Biologics Announces Pricing of $2.5 Million Public Offering (GlobeNewswire) -13.92% -26.96%
Sep-23-24 08:00AM	Theriva Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -10.00%
Sep-16-24 08:00AM	Theriva Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program (GlobeNewswire) -5.17%
Aug-26-24 11:51AM	Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested (TipRanks) -8.47%
Aug-16-24 04:05PM	Theriva Biologics Announces Reverse Stock Split (GlobeNewswire) -30.21%
Aug-13-24 08:09AM	Theriva Biologics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Theriva Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Jul-31-24 08:15AM	Theriva Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma (GlobeNewswire) -16.01%
May-23-24 08:15AM	Theriva Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -8.56%
May-14-24 08:00AM	Theriva Biologics to Participate in the A.G.P. Virtual Healthcare Conference (GlobeNewswire)
May-07-24 07:19AM	Theriva Biologics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Theriva Biologics Reports First Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Apr-25-24 08:15AM	Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +11.22%
Apr-23-24 07:00AM	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma (GlobeNewswire) -8.30%
Apr-22-24 04:35PM	Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting (GlobeNewswire)
Apr-08-24 08:00AM	Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 08:42AM	Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.18%
Mar-25-24 10:38PM	Q4 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.05%
07:30AM	Theriva Biologics Reports Full-Year 2023 Operational Highlights and Financial Results (GlobeNewswire)
Mar-19-24 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results (GlobeNewswire)
Mar-11-24 08:00AM	Theriva Biologics to Participate in the BIO-Europe Spring Conference (GlobeNewswire)
Feb-07-24 08:00AM	Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +14.58%
Jan-16-24 08:00AM	Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-20-23 05:56PM	Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call Transcript (Insider Monkey) +9.73%
Nov-14-23 03:14AM	Q3 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -10.86%
Nov-13-23 08:15AM	Theriva Biologics: Q3 Earnings Snapshot (Associated Press Finance) -6.34%
08:00AM	Theriva Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-06-23 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire) +7.23% -11.28%
Nov-02-23 04:15PM	Theriva Biologics to Participate in the BIO-Europe Conference (GlobeNewswire)
08:00AM	Theriva Biologics and Sant Joan de Déu-Barcelona Childrens Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer (GlobeNewswire)
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-23-23 07:00AM	Theriva Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 (GlobeNewswire)
Oct-16-23 08:00AM	Theriva Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) +5.90%
Sep-28-23 08:00AM	Theriva Biologics to Participate in the Emerging Growth Conference (GlobeNewswire)
Aug-08-23 10:43PM	Q2 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
08:37AM	Theriva Biologics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Theriva Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	Theriva Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +5.68%
Aug-01-23 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Jun-27-23 04:10PM	Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer (GlobeNewswire) +16.56% +14.79%
May-23-23 08:00AM	Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery (GlobeNewswire)
May-11-23 10:22PM	Q1 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Theriva Biologics: Q1 Earnings Snapshot (AP Finance)
08:00AM	Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
May-04-23 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire) +14.01%
Apr-13-23 08:00AM	Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire) +7.58%
Mar-30-23 08:00AM	Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Mar-24-23 04:05PM	Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Mar-20-23 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Feb-16-23 12:05PM	Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Jan-17-23 04:05PM	Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +7.93%
08:00AM	Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Jan-09-23 08:00AM	Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors (GlobeNewswire) +12.41%
Dec-06-22 07:00AM	Sidoti's December Small-Cap Virtual Conference (ACCESSWIRE)
Dec-01-22 08:00AM	Theriva Biologics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-22 04:45PM	Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
07:00AM	Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
Nov-03-22 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
08:00AM	Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Oct-31-22 08:00AM	Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics (GlobeNewswire)

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

CEOMr. Steven A. Shallcross CPA

Senior Vice President of Corporate & Product DevelopmentDr. Vince Wacher Ph.D.

Senior Vice President of DiscoveryDr. Ramon Alemany Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

TOVX

Theriva Biologics Inc

Upgrade your Finviz experience